

REMARKS/ARGUMENTS

The first sentence of the specification under the heading "Cross Reference to Related Applications" is amended to reflect the issuance of the parent application as US 6,794,537.

Claim 1 is amended to recite "a composition comprising Se-methyl-L-selenocysteine" to correct the indefiniteness in the wording of the original claim.

In light of the examiner's rejection of Claim 1 under 35 U.S.C 102(b) as being anticipated by prior art, along with the identification of Claim 2 as allowable subject matter, Claim 2 is now amended and presented as an independent claim.

To address the claim objections made by the examiner, claims 4, 6, and 7 are now amended to depend on independent claim 2, with recitation in proper dependent form, and claims 3, 5 and 8 are canceled.

As advised in the Office communication, replacement drawings free from extraneous dotted gray lines are now presented for examination.

Applicants respectfully request that a timely Notice of Allowance be issued in this case.

Respectfully submitted,

SABINSA CORPORATION

By Muhammed Majeed

Dr. Muhammed Majeed
Chief Executive Officer

Certificate of Mailing by "Express Mail"

"Express Mail" mailing label number ED 342653390 US
I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on April 11, 2005.
Date

Muhammed Majeed
Signature of person mailing correspondence

Dr. Muhammed Majeed
Typed or printed name of person mailing correspondence

Appl. No. 10/707,716
Am dt. dated April 8, 2005
Reply to Office action of January 13, 2005

Amendments to the Drawings:

The attached sheets of drawings include replacement Figures 1-6 that are free from extraneous dotted gray lines.